Abstract

Delafloxacin is a new broad-spectrum fluoroquinolone agent. It has the common bicyclic quinolone ring with additional substitutions namely, a chlorine in position C8 and a heteroaromatic ring in position N1. Mechanism of action of delafloxacin is the inhibition of bacterial DNA synthesis, it targets both bacterial gyrase and topoisomarase IV enzymes. During in vitro and in vivo investigations delafloxacin exhibited bactericid effect against several major pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Neisseria gonorrhoeae. Clinical trials have showed that delafloxacin is effective in skin and soft tissue infection caused by S. aureus, even against ciprofloxacin resistant pathogens. Delafloxacin was well-tolerated during both per os and parenteral administrations. Based on its pharmacokinetic and pharmacodynamic features delafloxacin can be a potential antimicrobial agent in therapy of acute bacterial skin and soft tissue infections and in community-acquired pneumonia in the future.